Tumor markers are molecules that indicate the presence of malignancy. They
are potentially useful in cancer screening, aiding diagnosis, assessing pro
gnosis, predicting in advance a likely response to therapy, and monitoring
patients with diagnosed disease. Because of the low prevalence of most canc
ers in the general population and the limited sensitivity and specificity o
f available markers, these tests alone are generally of little value in scr
eening for cancer in healthy subjects. Currently, however, PSA in combinati
on with digital rectal examination and CA 125 together with ultrasound are
undergoing evaluation us screening modalities for prostate and ovarian canc
er, respectively. Again, because of a lack of sensitivity and specificity,
markers are rarely of use in the early diagnosis of cancer. As prognostic i
ndicators, markers may provide information that is independent of tradition
ally used factors or within subgroups defined by traditional criteria, for
example, urokinase plasminogen activator in node-negative breast cancer. At
present, the best available marker for predicting response to therapy is t
he estrogen receptor for selecting hormone-sensitive breast cancers. Many d
ifferent markers can be used in the surveillance of patients with diagnosed
malignancies, the most useful of these being HCG in trophoblastic disease
and both AFP and HCG for nonseminomatous testicular germ cell tumors. In ge
neral, thr:currently available tu mor markers lack sensitivity for early ca
ncer and specificity fur malignancy. The goal of future research should he
to develop more sensitive and specific markers, especially for the common c
ancers.